Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Banque Cantonale Vaudoise

by · The Cerbat Gem

Banque Cantonale Vaudoise boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 354.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,182 shares of the pharmaceutical company’s stock after purchasing an additional 8,720 shares during the period. Banque Cantonale Vaudoise’s holdings in Vertex Pharmaceuticals were worth $5,201,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Creative Planning increased its position in Vertex Pharmaceuticals by 5.3% in the 2nd quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock worth $37,084,000 after purchasing an additional 3,998 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Vertex Pharmaceuticals by 640.0% in the 2nd quarter. Blue Trust Inc. now owns 1,443 shares of the pharmaceutical company’s stock valued at $676,000 after buying an additional 1,248 shares in the last quarter. Manning & Napier Advisors LLC acquired a new stake in Vertex Pharmaceuticals during the second quarter valued at approximately $74,213,000. Mizuho Securities USA LLC grew its position in Vertex Pharmaceuticals by 289.0% in the third quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after acquiring an additional 57,497 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth about $21,008,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Royal Bank of Canada upped their price target on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. decreased their target price on Vertex Pharmaceuticals from $510.00 to $503.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. Citigroup assumed coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 price target on the stock. Finally, Piper Sandler increased their price objective on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Three analysts have rated the stock with a sell rating, nine have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $499.12.

Get Our Latest Analysis on Vertex Pharmaceuticals

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $467.01 on Tuesday. The business’s fifty day simple moving average is $476.31 and its two-hundred day simple moving average is $472.56. Vertex Pharmaceuticals Incorporated has a 12 month low of $346.29 and a 12 month high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.67 EPS. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.82 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the sale, the chairman now directly owns 9,994 shares of the company’s stock, valued at $4,987,006. The trade was a 27.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Sangeeta N. Bhatia sold 646 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. This trade represents a 12.71 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Recommended Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).